Neil Desai Biography and Net Worth

Chairman of Aadi Bioscience

Dr. Desai is the founder of Aadi Bioscience, a director on the Company’s board and served as President and CEO from 2011 through 2022. Prior to that, he served as President and CEO since 2011. He is the inventor of nab technology and the mTOR inhibitor nab-sirolimus (FYARRO) and helped guide the organization through the drug development process leading to approval of FYARRO, the first FDA approved therapy for advanced malignant perivascular epithelioid cell tumor (PEComa). The Company raised $155M concurrent with a public listing in August 2021 and since that time, has grown to more than 80 employees including the recruitment of a top-notch leadership team. He has helped to guide the organization through the inaugural commercialization of FYARRO for advanced malignant PEComa, and the launch of the PRECISION 1 tumor-agnostic trial targeting TSC1 and TSC2 inactivating alterations. Most recently, following completion of a $72.5 million financing in September 2022, the Company launched a new clinical collaboration exploring the potential of the combination of nab-sirolimus with a KRAS inhibitor in NSCLC and other cancers.

What is Neil Desai's net worth?: The estimated net worth of Neil Desai is at least $5.67 million as of September 3rd, 2024. Dr. Desai owns 1,171,543 shares of Aadi Bioscience stock worth more than $5,670,268 as of August 28th. This net worth evaluation does not reflect any other assets that Dr. Desai may own. Learn More about Neil Desai's net worth.
How do I contact Neil Desai?: The corporate mailing address for Dr. Desai and other Aadi Bioscience executives is 9987 Carver Rd, Blue Ash, Ohio 45242-5550. Aadi Bioscience can also be reached via phone at (424) 473-8055 and via email at [email protected]. Learn More on Neil Desai's contact information.
Has Neil Desai been buying or selling shares of Aadi Bioscience?: Neil Desai has not been actively trading shares of Aadi Bioscience during the last quarter. Most recently, Neil Desai sold 40,000 shares of the business's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $1.71, for a transaction totalling $68,400.00. Following the completion of the sale, the chairman now directly owns 1,171,543 shares of the company's stock, valued at $2,003,338.53. Learn More on Neil Desai's trading history.
Who are Aadi Bioscience's active insiders?: Aadi Bioscience's insider roster includes Caley Castelein (Director), Neil Desai (Chairman), Scott Giacobello (CFO), and David Lennon (CEO). Learn More on Aadi Bioscience's active insiders.
Are insiders buying or selling shares of Aadi Bioscience?: During the last twelve months, insiders at the sold shares 1 times. They sold a total of 1,000 shares worth more than $389,830.00. The most recent insider tranaction occured on July, 13th when Director Karen Golz sold 1,000 shares worth more than $389,830.00. Insiders at Aadi Bioscience own 37.3% of the company. Learn More about insider trades at Aadi Bioscience.
Information on this page was last updated on 7/13/2026.

Neil Desai Insider Trading History at Aadi Bioscience

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/3/2024	Sell	40,000	$1.71	$68,400.00	1,171,543
8/5/2024	Sell	5,652	$1.34	$7,573.68	1,211,543
8/1/2024	Sell	15,415	$1.50	$23,122.50	1,236,128
7/1/2024	Sell	31,348	$1.45	$45,454.60	1,260,195
5/1/2024	Sell	40,000	$1.93	$77,200.00	1,331,543
4/1/2024	Sell	17,772	$2.31	$41,053.32	1,393,771
3/4/2024	Sell	14,964	$2.10	$31,424.40	1,411,543
3/1/2024	Sell	27,036	$1.97	$53,260.92	1,426,507
2/1/2024	Sell	42,000	$1.74	$73,080.00	1,453,543
1/2/2024	Sell	42,000	$2.06	$86,520.00	1,495,543
12/6/2023	Sell	7,037	$4.82	$33,918.34	1,537,543
12/4/2023	Sell	10,876	$5.15	$56,011.40	1,560,320
12/1/2023	Sell	8,347	$5.14	$42,903.58	1,571,196
11/1/2023	Sell	10,338	$4.32	$44,660.16	1,611,205
10/2/2023	Sell	25,569	$4.37	$111,736.53	1,637,974
9/5/2023	Sell	21,000	$5.63	$118,230.00	1,670,654
9/1/2023	Sell	13,889	$5.97	$82,917.33	1,691,654
8/1/2023	Sell	22,710	$5.22	$118,546.20	1,724,833
7/5/2023	Sell	16,171	$6.55	$105,920.05	1,763,372
7/3/2023	Sell	10,000	$6.64	$66,400.00	1,779,543
6/5/2023	Sell	17,315	$8.11	$140,424.65	1,796,803
6/1/2023	Sell	4,982	$7.92	$39,457.44	1,826,561
5/3/2023	Sell	7,695	$7.68	$59,097.60	1,833,848
5/1/2023	Sell	24,479	$7.80	$190,936.20	1,849,064
4/5/2023	Sell	7,336	$7.24	$53,112.64	1,885,755
4/3/2023	Sell	9,583	$7.45	$71,393.35	1,905,960
3/18/2022	Sell	3,550	$20.07	$71,248.50

Neil Desai Buying and Selling Activity at Aadi Bioscience

Aadi Bioscience Company Overview

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Today's Range

Now: $4.84

$4.83

$5.10

50 Day Range

MA: $4.25

$3.66

$5.08

2 Week Range

Now: $4.84

$1.21

$3.81

Volume

136,263 shs

Average Volume

261,100 shs

Market Capitalization

$119.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68